Abstract 1664P
Background
Despite important implications for patient outcomes, psycho-oncology care (POC) remains underappreciated in low-middle income countries like India. Screening in our patient population revealed high distress levels, among both patients/caregivers and emphasized barriers in accessing mental health care. Our study tests a model of care which proposes early integration of POC in a clinical cancer care setting.
Methods
A multidisciplinary team of ten healthcare professionals, including oncologists, psychologists, oncology nurses and social workers, developed the proposed model. The key components and interventions were: (1) linking counsellor consultation with first patient registration (2) co-counselling of patients and caregivers pre, during and post treatment (3) accessibility of psychologists in inpatient departments through joint ward rounds with treating clinician.
Results
Between Dec 2023 to Mar 2024, 1674 patients reported to Radiation Oncology OPD and 265 had inpatient admissions. The implementation of this model resulted in 31.9% increase in psychological counsellor consultations for outpatients (5.4% to 37.3%), and 82.6% increase for inpatients (12.2% to 94.8%). It also showed 62.68% increase in co-counselling (16.6% to 79.46%). Counsellors flagged off important issues like fear of recurrence or infertility, intimacy issues and reluctance to continuing therapy which patients were hesitant in sharing with the treating physician. Patient reported satisfaction levels evaluated using the OUT-PATSAT35 questionnaire also increased from 62% to 75%.
Conclusions
This model highlights simple ways to prioritise accessibility to mental healthcare in resource limited settings, without adding to the physician work burden and resulting in positive patient outcomes. Increased counsellor accessibility could also be attributed to employing more manpower (3 counsellors versus 1 prior to the study). Despite advising counselling at first contact, not all patients reported for it highlighting a significant barrier to mental therapy. Longer follow up is warranted to evaluate this model’s effectiveness and sustainability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N.Bisht.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11